Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Regeneron Pharmaceuticals Inc (REGN) reports robust financial performance with a 10% revenue increase and unveils new ...

We expect regulatory approvals for linvoseltamab in relapsed/refractory multiple myeloma, odronextamab in late-line follicular lymphoma, and the aforementioned Libtayo indication in adjuvant CSCC.

Regeneron hopes for approval in the indication in the second half of this year. Regeneron also is studying Libtayo as a combo therapy with the company’s fianlimab, going up against Keytruda ...

Per The Athletic's Josh Robbins, "all indications are that Kuzma is less patient now with the Wizards' direction" than he was a season ago. According to Robbins, Monumental Basketball president ...

In Q1 2025, they also aim to share results from two additional studies, with an NDA submission expected later this year. The company plans to conduct further studies on cebranopadol in multiple ...

A significant type of these IP rights is Geographical Indication (GI). A geographical indication is a distinctive sign, mark or name that distinguishes products, goods and services based on their ...

“These positive results add to the case that NeuroRestore ACD856 could be relevant for additional indications with an inflammatory component, such as other neurodegenerative diseases,” said Martin ...